Home » Stocks » PLRX

Pliant Therapeutics, Inc. (PLRX)

Stock Price: $26.50 USD 0.42 (1.61%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 940.22M
Revenue (ttm) 94.40M
Net Income (ttm) 19.66M
Shares Out 35.45M
EPS (ttm) 0.55
PE Ratio 47.77
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $26.50
Previous Close $26.08
Change ($) 0.42
Change (%) 1.61%
Day's Open 25.61
Day's Range 25.36 - 26.80
Day's Volume 49,207
52-Week Range 19.89 - 35.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel ...

Seeking Alpha - 2 months ago

PLRX has a pipeline targeting various fibrotic diseases. It has in-licensed technology from the UCSF, and collaborations with Novartis.

PRNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing ...

PRNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel thera...

PRNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 4, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.

PRNewsWire - 4 months ago

SAN FRANCISCO, Aug. 27, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.

PRNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.

The Motley Fool - 7 months ago

There's a chance that it could become an even bigger success story.

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 5, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel thera...

GuruFocus - 7 months ago

Pliant Therapeutics Inc. (NASDAQ:PLRX) has knocked it out of the park since joining the ranks of public companies on Wednesday.

The Motley Fool - 7 months ago

Investors are excited about the biotech's prospects, but the company still has a long road ahead.

Market Watch - 7 months ago

Pliant Therapeutics Inc. shares PLRX, +56.25% soared 55% in their trading debut Wednesday, after the company's initial public offering priced at $16 a share, the high end of its $14 to $16 range.

About PLRX

Pliant Therapeutics, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecul... [Read more...]

Industry
Biotechnology
IPO Date
Jun 3, 2020
CEO
Bernard Coulie
Employees
70
Stock Exchange
NASDAQ
Ticker Symbol
PLRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for PLRX stock is "Buy." The 12-month stock price forecast is 43.33, which is an increase of 63.51% from the latest price.

Price Target
$43.33
(63.51% upside)
Analyst Consensus: Buy